Palatin Technologies

Palatin Technologies, Inc. is a biopharmaceutical company, which engages in the development of medicines based on molecules that modulate the activity of the melanocortin receptor system. Its primary product candidate is marketed under the Vyleesi brand, the trade name for bremelanotide, which is used for the treatment of premenopausal women with acquired, generalized, hypoactive sexual desire disorder (HSDD). The company was founded by Carl Spana and John K. A. Prendergast on November 21, 1986 and is headquartered in Cranbury, NJ.

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q2 2025

Palatin Technologies reports revenue challenges but advances pipeline programs

Palatin Technologies faced revenue challenges in Q3 2024 but showcased strengths in pipeline advancements and positive clinical results.
The company's financial performance improved despite increased operating expenses, with a focus on expanding clinical programs and enhancing drug profiles.
While facing cash utilization concerns and upcoming study expenses, Palatin remains optimistic about its progress and future milestones.

Palatin Technologies reports Q4 loss, progresses in ocular treatments

Palatin Technologies navigated Q4 2024 with a focus on cost reduction and asset sales, impacting revenue and expenses.
Despite financial challenges, the company's progress in ocular programs and pipeline development showcases strategic advancements.
Opportunities lie in leveraging asset sale proceeds, advancing clinical programs, and addressing funding needs for future growth.

Palatin Technologies focuses on obesity programs amid financial challenges

Palatin Technologies navigated challenges in Q1 2024 with no product sales and a net loss, while managing operating expenses effectively.
The company's focus on core obesity programs and upcoming study results indicate strategic alignment and progress in key initiatives.
Despite financial constraints and timing risks, Palatin's exploration of strategic options and pipeline advancement offer growth opportunities.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Palatin Technologies, Inc. (PTN) delivered earnings and revenue surprises of 0% and 62.76%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Palatin Technologies, Inc. (PTN) Reports Q3 Loss, Misses Revenue Estimates

Patient Enrollment on Track in Phase 3 Pivotal Study of PL9643 in Patients with Dry Eye Disease with Topline Results Currently Expected Second Half Calendar 2022 Vyleesi® - Gross product sales increased 67%, net product revenue increased 200% and prescriptions dispensed increased 20%, over the prior quarter Closed on a $15 Million Private Placement of Convertible Redeemable Preferred Stock Phase 2 Clinical Study of PL8177 in Patients with Ulcerative Colitis Expected to Start Next Month with Topline Results Currently Expected First Quarter Calendar 2023 Teleconference and Webcast to be held on May 17, 2022 at 11:00 AM EDT CRANBURY, N.J. , May 17, 2022 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin and natriuretic peptide receptor systems, today announced results for its fiscal third quarter ended March 31, 2022.

Palatin Reports Third Quarter Fiscal Year 2022 Financial Results and Provides Corporate Update

CRANBURY, N.J. , May 12, 2022 /PRNewswire/ -- Palatin Technologies, Inc. ("Palatin" or the "Company") (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin peptide receptor system, today announced  that it has entered into a securities purchase agreement with institutional investors pursuant to which Palatin will issue and sell 8,100,000 shares of its Series B convertible redeemable preferred stock and 900,000 shares of its Series C convertible redeemable preferred stock to such investors.

Palatin Announces $15 Million Private Placement of Convertible Redeemable Preferred Stock

CRANBURY, N.J. , May 11, 2022 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN) will announce its third quarter, fiscal year 2022 operating results on Tuesday, May 17, 2022, before the open of the U.S. financial markets.

Palatin to Report Third Quarter, Fiscal Year 2022 Results; Teleconference and Webcast to be held on May 17, 2022

Posters highlight Palatin's ocular research and PL9643 Phase 2 clinical data CRANBURY, N.J. , May 2, 2022 /PRNewswire/ -- Palatin Technologies, Inc. ("Palatin") (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin peptide receptor system, today announced two poster presentations at the Association for Research in Vision and Ophthalmology (ARVO) Annual Conference being held May 1-4 in Denver.

Palatin to Present at the Association for Research in Vision and Ophthalmology (ARVO) 2022 Annual Conference

Presentation to review the role of melanocortins in the treatment of ocular disease and Phase 2 study results with Palatin's compound PL9643 for Dry Eye Disease PL9643 Dry Eye Disease Phase 3 study ongoing - data expected 4Q 2022 CRANBURY, N.J. , April 21, 2022 /PRNewswire/ -- Palatin Technologies, Inc. ("Palatin") (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin peptide receptor system, today announced that Carl Spana, Ph.D.

Palatin to Present at Eyecelerator @ American Society of Cataract and Refractive Surgery (ASCRS) 2022

Agile Therapeutics

Brickell Biotech Inc

IT Tech Packaging Inc

Popular Reddit penny stocks to watch under $1. The post Best Penny Stocks Today?

Best Penny Stocks Today? 4 To Buy For Under $1 According To Reddit

CRANBURY, N.J. , March 3, 2022 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin and natriuretic peptide receptor systems, today announced that it will host a key opinion leader (KOL) webinar on the unmet medical need in treating patients with dry eye disease (DED) on Monday, March 7, 2022 at 10:30 am ET.

Palatin Hosting Key Opinion Leader Webinar on Dry Eye Disease

Palatin Technologies is an overlooked micro-cap which has exceptional future potential in their FDA approved drug, Vyleesi, but has struggled with many challenges over the course of the pandemic.

Palatin Technologies: A Diamond In The Rough

Palatin Technologies, Inc. (PTN) CEO Carl Spana on Q2 2022 Results - Earnings Call Transcript

CRANBURY, N.J., Feb. 15, 2022 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin and natriuretic peptide receptor systems, today announced results for its fiscal second quarter ended December 31, 2021.

Palatin Reports Second Quarter Fiscal Year 2022 Financial Results and Provides Corporate Update

Palatin Technologies, Inc. (PTN) delivered earnings and revenue surprises of -33.33% and 78.89%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Palatin Technologies, Inc. (PTN) Reports Q2 Loss, Tops Revenue Estimates

CRANBURY, N.J., Feb. 10, 2022 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN) will announce its second quarter, fiscal year 2022 operating results on Tuesday, February 15, 2022, before the open of the U.S. financial markets.

Palatin to Report Second Quarter, Fiscal Year 2022 Results; Teleconference and Webcast to be held on February 15, 2022

Palatin Technologies, Inc. (PTN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Palatin Technologies, Inc. (PTN) May Report Negative Earnings: Know the Trend Ahead of Q2 Release

CRANBURY, N.J., Jan. 21, 2022 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin peptide receptor system, announced a presentation of the positive effects of PL8177 on treating ulcerative colitis in an animal disease model, including genomic data characterizing the anti-inflammatory effects of melanocortin agonists.

Palatin Announces Presentation at the 2022 Crohn's and Colitis Congress

CRANBURY, N.J., Jan. 7, 2022 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a specialized biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin peptide receptor system, announced that the Company will present and host one-on-one meetings at the H.C.

Palatin to Present at H.C. Wainwright BioConnect Conference

OPKO Health

Senseonics Holdings

Add these three penny stocks to your January 2022 watchlist The post Which Penny Stocks Are Investors Watching in 2022? 3 To Check Out appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Which Penny Stocks Are Investors Watching in 2022? 3 To Check Out

Palatin (PTN) commences the pivotal phase III study evaluating PL9643 for the treatment of dry eye disease. Top-line data from the same is expected in the second half of 2022.

Palatin (PTN) Begins Phase III Study For Dry Eye Disease

CRANBURY, N.J., Dec. 28, 2021 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a specialized biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin peptide receptor system, announced the initiation of the pivotal Phase 3 MELODY-1 clinical study of PL9643 in patients with dry eye disease.

Palatin Announces Initiation of Pivotal Phase 3 PL9643 MELODY-1 Clinical Trial in Patients with Dry Eye Disease

Gran Tierra Energy

Powerbridge Technologies Co Ltd

Sesen Bio Inc.

Cheap penny stocks to watch this week. The post 4 Penny Stocks To Buy For Under $1 On Webull appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

4 Penny Stocks To Buy For Under $1 On Webull

Reliance Global Group

TOMI Environmental Solutions

Are these on your penny stocks watch list this week? The post 3 Top Penny Stocks To Watch Under $4 This Week appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

3 Top Penny Stocks To Watch Under $4 This Week

Matinas BioPharma Hlds

Looking for cheap penny stocks to buy? Here are 4 to watch trading below $1 right now.

Penny Stocks To Buy For Under $1 & What To Watch Right Now

With several high-conviction treatments in its pipeline, Palatin Technologies is delivering results -- and PTN stock may be ready to run soon. The post Keep Your Eye On Palatin Technologies as $5 Price Target Gets Attention appeared first on InvestorPlace.

Keep Your Eye On Palatin Technologies as $5 Price Target Gets Attention

Palatin Technologies, Inc. (PTN) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.

Here's Why Palatin Technologies, Inc. (PTN) Is a Great 'Buy the Bottom' Stock Now

iBio

Qualigen Therapeutics

Trading biotech penny stocks right now? Check these three out The post Hot Biotech Penny Stocks to Buy Today?

News for Palatin Technologies Stock (PTN)